Hani Oweira1,2, Ulf Petrausch3, Daniel Helbling4, Jan Schmidt5, Arianeb Mehrabi2, Othmar Schöb5, Anwar Giryes1, Omar Abdel-Rahman1,6. 1. a Cancer Research Department , Swiss Cancer Institute , Cham , Switzerland . 2. b Department of General, Visceral and Transplant Surgery , University of Heidelberg , Heidelberg , Germany. 3. c Tumot immunology Department , Swiss Tumor Immunology Institute (SwissTII) , Zurich , Switzerland. 4. d Medical oncology , Gastrointestinal Tumor Center Zurich (GITZ) , Zurich , Switzerland. 5. e Surgery Department , Surgical Center Zurich - Hirslanden Hospital Zurich , Switzerland. 6. f Clinical Oncology Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
Abstract
BACKGROUND: We the prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma (HCC) patients registered within the surveillance, epidemiology and end results (SEER) database. METHODS: SEER database (2010-2013) has been queried through SEER*Stat program to determine the prognosis of advanced HCC patients according to the site of extra-hepatic disease. Survival analysis has been conducted through Kaplan Meier analysis. RESULTS: A total of 4396 patients with stage IV HCC were identified in the period from 2010-2013 and they were included into this analysis. Patients with isolated regional lymph node involvement have better outcomes compared to patients with any other site of extra-hepatic disease (P < 0.0001 for both endpoints). Among patients with distant metastases, patients with bone metastases have better outcomes compared to patients with lung metastases (P < 0.0001 for both endpoints). Multivariate analysis revealed that younger age, normal alpha fetoprotein, single site of extra-hepatic disease, local treatment to the primary tumor and surgery to the metastatic disease were associated with better overall survival and liver cancer-specific survival. CONCLUSION: Within the limits of the current SEER analysis, HCC patients with isolated lung metastases seem to have worse outcomes compared to patients with isolated bone or regional nodal metastases..
BACKGROUND: We the prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma (HCC) patients registered within the surveillance, epidemiology and end results (SEER) database. METHODS: SEER database (2010-2013) has been queried through SEER*Stat program to determine the prognosis of advanced HCCpatients according to the site of extra-hepatic disease. Survival analysis has been conducted through Kaplan Meier analysis. RESULTS: A total of 4396 patients with stage IV HCC were identified in the period from 2010-2013 and they were included into this analysis. Patients with isolated regional lymph node involvement have better outcomes compared to patients with any other site of extra-hepatic disease (P < 0.0001 for both endpoints). Among patients with distant metastases, patients with bone metastases have better outcomes compared to patients with lung metastases (P < 0.0001 for both endpoints). Multivariate analysis revealed that younger age, normal alpha fetoprotein, single site of extra-hepatic disease, local treatment to the primary tumor and surgery to the metastatic disease were associated with better overall survival and liver cancer-specific survival. CONCLUSION: Within the limits of the current SEER analysis, HCCpatients with isolated lung metastases seem to have worse outcomes compared to patients with isolated bone or regional nodal metastases..